National Institutes of Health: Influenza, Human trials

The registry lists 190 Influenza, Human studies with National Institutes of Health as lead sponsor. 12 are open to participants now and 54 have results posted.

Phase 1 96Phase 2 70Phase 3 5Phase 4 11No phase 27(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & AdolescentsCompletedNCT01609998Phase 1
• H5N1 Vaccination With and Without AS03: Systems Biology AnalysisCompletedNCT01573312Phase 1
• Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy AdultsCompletedNCT01534468Phase 1
• Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV AloneCompletedNCT01498718Phase 1
• Experimental AD4-H5-VTN Vaccine in Healthy VolunteersCompletedNCT01443936Phase 1
• Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza VaccineCompletedNCT01443663Phase 1
• H5N1 Mix and Match With AS03CompletedNCT01317758Phase 1
• H5N1 Mix and Match With MF59CompletedNCT01317745Phase 1
• Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.CompletedNCT01262079
• A Study of the Pharmacology of Tamiflu in PregnancyCompletedNCT01203527
• Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza VaccinesCompletedNCT01191853
• Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 InfluenzaCompletedNCT01175122Phase 1
• Influenza Antiviral DAS181-F03CompletedNCT01173224Phase 1
• Comparison of Flu Vaccine Doses in ChildrenCompletedNCT01164553Phase 1
• Blood and Plasma Collection For Use in Future Clinical TrialsCompletedNCT01136057
• An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...CompletedNCT01086657Phase 1
• Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 VaccinesCompletedNCT01086566Phase 1
• Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With InfluenzaWithdrawnNCT01063933Phase 1/2
• Novel Influenza A (H1N1) Surveillance RegistryCompletedNCT01046331
• Safety and Efficacy of Oseltamivir in Children Younger Than One Year of AgeWithdrawnNCT01037634Phase 2
• VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 YearsCompletedNCT00995982Phase 1
• A Pilot Study for Collection of Anti-Influenza A Immune PlasmaCompletedNCT00984451
• VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years OldCompletedNCT00973895Phase 1
• CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly PopulationsWithdrawnNCT00964951Phase 2
• Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7CompletedNCT00922259Phase 1
• Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59CompletedNCT00912496Phase 1
• Nontypeable H. Influenzae in Healthy AdultsCompletedNCT00905385Phase 1/2
• VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...CompletedNCT00858611Phase 1
• Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy AdultsCompletedNCT00853255Phase 1
• Vaccine for Prevention of Bird FluCompletedNCT00776711Phase 1
• High Dose Influenza in Immunosuppressed SubjectsWithdrawnNCT00766285Phase 2
• Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine VaccineCompletedNCT00734175Phase 1
• Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus VaccineCompletedNCT00722774Phase 1
• H5N1 (Clade 2) Vaccination of Adults and ElderlyCompletedNCT00680069Phase 1/2
• H9 Priming Study in Healthy AdultsCompletedNCT00617331Phase 2
• Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy AdultsCompletedNCT00546585Phase 1/2
• Influenza in People With Normal and Weakened Immune SystemsCompletedNCT00533182
• Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy AdultsCompletedNCT00516035Phase 1
• Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given IntradermallyCompletedNCT00489931Phase 1
• Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy AdultsCompletedNCT00488046Phase 1
• Clinical IGSP-CHOP BostonCompletedNCT00428831
• China Case Control Avian InfluenzaCompletedNCT00428753
• Prospective Study of AI H5N1 in ChinaCompletedNCT00428493
• Pilot Study of Genotypic AnalysisCompletedNCT00421837
• Inpatient Influenza SurveillanceCompletedNCT00419861
• Safety Study of Avian Flu VaccineCompletedNCT00408109Phase 1
• Th1 Response to Influenza: Aging and Vaccine EfficacyTerminatedNCT00396305Phase 4
• Proteomic Profiling for Influenza Vaccination - FluMistCompletedNCT00385281Phase 4
• Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in AdultsCompletedNCT00382980Phase 1
• Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)CompletedNCT00380237Phase 1
• Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy AdultsCompletedNCT00347672Phase 1
• T and B Cell Response to Avian Flu VaccineCompletedNCT00337896
• Pharma-Pen (Formerly Innoject) Auto-injectory TIVWithdrawnNCT00335855Phase 1
• Alternative Oseltamivir Dosing StrategiesCompletedNCT00334529Phase 2
• Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in AdultsCompletedNCT00333398Phase 3
• Cell-Mediated Immune Responses to Influenza A/H5N1 VaccineCompletedNCT00311727Not applicable
• Chart Review of Antivirals for Influenza in InfantsCompletedNCT00311701
• St. Jude Open Label H5 TrialCompletedNCT00311675Phase 1/2
• Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing FacilitiesCompletedNCT00311649Phase 1/2
• H5N1 Vaccine Intramuscular Versus Intradermal in Healthy AdultsCompletedNCT00310206Phase 1
• Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell LymphomaCompletedNCT00307177Phase 2
• Safety and Dose Study of Peramivir for Influenza TreatmentCompletedNCT00297050Phase 1
• H5 Vaccine Alone or With Adjuvant in Healthy AdultsCompletedNCT00296634Phase 1/2
• H5 Vaccine Alone or With Aluminum Hydroxide in Elderly AdultsCompletedNCT00294099Phase 1/2
• H5 Adult - Chiron Study of Bird Flu VaccineCompletedNCT00280033Phase 1/2
• Immunogenicity and Safety of Different Doses of Fluzone® InfluenzaCompletedNCT00253734Phase 2
• H5 Booster After a Two Dose ScheduleCompletedNCT00240968Phase 2
• Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) VaccineCompletedNCT00240903Phase 1
• Inactivated Influenza Vaccine in Infants 10-22 Weeks of AgeCompletedNCT00231920Phase 1
• A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and FlumistCompletedNCT00231907Phase 1
• Inactivated Influenza A/H5N1 Vaccine in the ElderlyCompletedNCT00230750Phase 1/2
• Comparison of Delivery Routes of Flu Vaccine in AdultsCompletedNCT00170547Phase 2
• Young Adult Influenza Vaccine Immunogenicity SubstudyCompletedNCT00170508Not applicable
• Elderly Influenza Vaccine Immunogenicity SubstudyCompletedNCT00170482
• Trivalent rHA Dose Escalation Study in Elderly SubjectsCompletedNCT00170443Phase 2
• T-cell Response-Flu Risk in Older AdultsCompletedNCT00138398Not applicable
• Comparison of Inactivated and Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age-Year 3 AmendmentCompletedNCT00138385Phase 4
• Influenza Immunity Against Pandemic Respiratory VirusCompletedNCT00138281Phase 4
• Proteomic Profiling for InfluenzaCompletedNCT00133588Phase 4
• A/H5N1 Vaccine in Healthy Children Aged 2-9 YearsCompletedNCT00133536Phase 1/2
• FLU-VACS Comparative Study in AdultsCompletedNCT00133523Phase 4
• Influenza Vaccine in Pediatric Transplant SubjectsCompletedNCT00133510Phase 4
• Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory AdultsCompletedNCT00133471Phase 1/2
• A/H5N1in Adult - AventisCompletedNCT00115986Phase 1/2
• Eldery High Dose TIV 2005CompletedNCT00115531Phase 2
• Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)CompletedNCT00110279Phase 1
• Fluarix Immunogenicity and Safety TrialCompletedNCT00100399Phase 3
• Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and AdolescentsCompletedNCT00091702Phase 1/2
• Half-Dose Flu Vaccine Study in Healthy AdultsCompletedNCT00006146Phase 2
• Study of a Flu Vaccine in ChildrenCompletedNCT00001127Phase 3